Abstract
Purpose: The completion rate and intensity of Capecitabine plus oxaliplatin (CapeOX) combination therapy are often low in clinical practice due to chemotherapy-induced nausea and vomiting (CINV). This open-label, prospective, multi-center phase II trial assessed the safety and efficacy of a granisetron transdermal delivery system (GTDS) and Dexamethasone for patients receiving CapeOX chemotherapy.
Methods: Patients received the GTDS (3.1 mg attached to the upper arm 48 h before chemotherapy, replaced on day 5 and discarded on day 12) and Dexamethasone. The primary endpoint was the complete control rate.
Results: Twenty-nine participants were enrolled. The complete control rate for delayed nausea and vomiting (25–480 hours) was 70.4% (95% CI 0.50–0.86). The acute phase complete control rate was 85.2% (95% CI 0.65–0.95). No serious adverse events were attributed to the antiemetic regimen.
Conclusion: Prolonged administration of the GTDS is safe and effective for preventing CINV in patients with gastrointestinal malignancies treated with CapeOX.
Introduction
The Capecitabine plus Oxaliplatin (CapeOX) regimen is a cornerstone of treatment for gastrointestinal cancers. However, it is notorious for causing CINV. While acute CINV (within 24 hours) is relatively well-managed, delayed CINV remains a major hurdle, with historical data showing only about 48.7% of patients achieve complete control with standard treatments. This study investigated whether a prolonged, 14-day administration of a granisetron transdermal patch (GTDS) could improve these outcomes by providing continuous, steady-state drug delivery.
Methods
This Phase II trial involved 29 patients across three institutions. The baseline characteristics of the cohort are detailed in Table 1.
The core innovation was the prolonged administration schedule of the GTDS:
- Patch 1: Applied 48 hours before chemotherapy and worn until Day 5.
- Patch 2: Applied on Day 5 and worn until Day 12.
- Co-medication: Oral Dexamethasone on Days 1 through 3.
Researchers monitored patients for a full 20-day cycle using daily diaries and the Functional Living Index-Emesis (FLIE) questionnaire.
Results
The study achieved its primary endpoint, showing a substantial improvement in symptom management. The complete control (CC) rate for delayed nausea and vomiting (25–480 hours) was 70.4%, significantly higher than historical benchmarks.
Key findings include:
- Acute Phase Success: The CC rate in the first 24 hours was 85.2%.
- Duration of Relief: Patients achieved an average of 17.1 ± 4.9 days of complete control during the 21-day cycle.
- Quality of Life: 59.3% of patients experienced no nausea during the delayed phase. Only 13.8% of patients required chemotherapy dose interruptions due to CINV.
- Safety: No significant QTc interval prolongation was observed, confirming cardiac safety. The most common side effect was constipation (27.5%).
Discussion
The steady-state delivery provided by the transdermal patch appears to effectively counter the persistent emetogenic stimulus of the CapeOX regimen. By extending the observation window to 20 days and utilizing the "Dates of Delayed Complete Control" (DDCC) metric, the study provides a more nuanced view of patient experience than traditional 5-day studies.
Limitations include the small sample size (N=29) and the single-arm design. Future randomized controlled trials are needed to confirm these results and optimize the patch replacement schedule, particularly addressing the efficacy dip observed around Day 4.
Conclusion
Prolonged GTDS administration is a safe and effective strategy for reducing CINV in patients undergoing CapeOX chemotherapy, supporting better treatment adherence and patient quality of life.
Summary updated